Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RDN-929 in Healthy Older Adults
NCT03963973Phase 1Terminated
- Sponsor
- Alkermes
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD), Parkinson's disease (PD) and frontotemporal dementia (FTD) comparing RDN-929 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events up to 9 weeks, Number of subjects with Physical exam findings up to 9 weeks and 4 more. Started May 2019; status: terminated.
02
Drugs
RDN-929
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT03963973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963973.